Echinacea (Echinacea purpurea)
In short
Summary of findings for quick reference
Echinacea is a North American prairie genus, and three species are used: Echinacea purpurea, E. angustifolia, and E. pallida. Its medicinal story is recent rather than ancient. The earliest written record is the Lewis and Clark journals of 1804, which note the use of the narrow-leaved coneflower among Plains nations such as the Cheyenne, Pawnee, and Sioux for snakebite, wounds, and sore throat. Nineteenth-century Eclectic physicians took the plant into their materia medica, and from the 1930s Echinacea purpurea became established in central-European phytotherapy.
Modern evidence is real but mixed and unusually product-dependent. The 2014 Cochrane review of 24 trials in nearly 5000 people found inconsistent results overall, with a modest signal only in a subgroup using Echinacea purpurea above-ground preparations begun within 24 hours of the first symptoms. The European Medicines Agency lists E. purpurea herb for cold-season use, with some preparations under well-established use and others under traditional use, which mirrors the same finding: the specific preparation and brand matter more for this plant than for most. Laboratory work on alkylamides and immune-cell activity is mechanistic and its relevance to symptoms in people is still debated.
Two practical points stand out. Echinacea is not suitable for everyone: it is not recommended in active autoimmune disease, under immunosuppression, in known allergy to daisy-family plants, or for children under 12 with most preparations, and pregnancy and lactation data are limited. And because results depend so heavily on the species, the plant part, and the specific product, choosing a well-documented preparation and following its label matters here. On our historical-significance axis echinacea sits at the regional tier: a well-documented but young tradition, founded by First Nations use and carried forward by Eclectic and modern European phytotherapy, not an ancient Old World herb.
Clinical evidence ↔ Historical significanceWe display two separate evidence categories: clinical evidence from modern trials and historical significance from documented healing tradition. Both are valuable, but they answer different questions.Read more
In every encyclopedia entry we evaluate two distinct categories of evidence. Clinical evidence as used in trials meets a narrower but scientifically essential bar. At the same time, the hundreds of thousands of plant species worldwide have only partially been captured and tested in modern studies.
Alongside the trial picture our researchers compile a comprehensive overview of where and since when a plant has been used across different traditions of natural medicine. When a plant has been used as a medicinal plant in many cultures across many generations, that historical significance deserves to be visible too.
Our position: a truly informative overview emerges only when both categories sit side by side. We communicate transparently what counts as what.
Overview
Echinacea is a genus of nine North-American prairie plants in the daisy family (Asteraceae), three of which are used medicinally: Echinacea purpurea, E. angustifolia, and E. pallida. Above-ground parts of E. purpurea, flower, leaf, stem, are the most-studied in modern clinical research.
The European Medicines Agency HMPC has registered Echinacea purpurea preparations under traditional-use plant medicines for cold-season support, alongside a body of clinical trial data. The Cochrane review found inconsistent results across products, which makes product choice unusually important for this botanical.
History
Echinacea was used extensively by Plains indigenous nations, particularly the Cheyenne, Comanche, Pawnee, and Sioux, for snakebite, wound healing, sore throat, and toothache. Anthropological surveys document E. angustifolia as one of the most-used medicinal plants of the central Great Plains.
European interest grew in the late 19th century through the Eclectic medical tradition in North America, then took root in central Europe in the 1930s, where Echinacea purpurea preparations became widely used. Most contemporary clinical evidence rests on European-style Echinacea purpurea preparations, not on the angustifolia preparations indigenous nations originally used.
Mechanism
Echinacea contains three classes of putatively active compounds: alkylamides (most concentrated in roots, especially E. angustifolia), caffeic-acid derivatives such as echinacoside and cichoric acid (most concentrated in flowers and above-ground parts of E. purpurea), and polysaccharides. Alkylamides bind cannabinoid CB2 receptors in vitro and have shown immunomodulatory effects in cell culture.
In healthy human volunteers, oral Echinacea preparations modestly increase phagocytic activity of macrophages and natural-killer-cell cytotoxicity. The clinical relevance of these in-vitro and ex-vivo signals to actual symptom reduction is debated and likely depends on whether the alkylamide-rich or polysaccharide-rich fraction predominates in a given product.
The Cochrane Review by Karsch-Völk et al. (2014) is the most authoritative summary: 24 RCTs covering nearly 5000 participants, with significant heterogeneity in preparation, dose, and outcome. The pooled analysis showed inconsistent results overall, but a subset of trials using E. purpurea above-ground preparations within 24 hours of symptom onset reported modest reductions in cold duration and severity.
Two large product-level studies are often cited: Goel et al. (2004, J Clin Pharm Therapeutics) using a proprietary E. purpurea preparation reduced cold duration by 1.4 days vs placebo in 282 adults; Jawad et al. (2012, Evidence-Based Complementary Medicine) using a 3-component Echinacea preparation prophylactically over 4 months reported fewer cold episodes and reduced antibiotic use. Other trials show no effect.
EMA HMPC accepts a "well-established use" label for some E. purpurea preparations and a "traditional use" label for others, reflecting the same product-dependent finding the Cochrane review identified. For consumers, this means the brand and preparation matter more than for most botanicals.
Evidence
| Outcome | Class | Grade | Effect | Studies | Refs |
|---|---|---|---|---|---|
| Traditional cold-season support (EMA HMPC) | TraditionalTraditional use. Long-standing folk practice or EMA HMPC traditional-use monograph. | IEvidence quality grade I (Insufficient). Not enough evidence to draw a conclusion. More research needed. This is an evidence rating, not a product endorsement. | EMA HMPC traditional-use registration for E. purpurea above-ground preparations to relieve cold-season symptoms. Framing per traditional use, not a clinical treatment. | ||
| Cold duration in subgroup analyses | EmergingEmerging research. Early small trials suggest an effect but await replication. | IEvidence quality grade I (Insufficient). Not enough evidence to draw a conclusion. More research needed. This is an evidence rating, not a product endorsement. | Karsch-Volk 2014 Cochrane review of 24 RCTs found inconsistent results overall; a subgroup of E. purpurea above-ground preparations started within 24h of onset showed modest signal. | ||
| In vitro immune cell modulation | EmergingEmerging research. Early small trials suggest an effect but await replication. | IEvidence quality grade I (Insufficient). Not enough evidence to draw a conclusion. More research needed. This is an evidence rating, not a product endorsement. | Alkylamides and polysaccharides modulate macrophage and NK cell activity in laboratory studies. Mechanistic only; clinical translation is product-dependent and debated. |
Usage
Forms and preparation
Quality-controlled E. purpurea above-ground preparations are the format with the strongest body of clinical evidence. Three forms dominate: hydroalcoholic fresh-plant tincture (the Madaus tradition), pressed-juice preparations stabilised with small amounts of alcohol, and standardised extract capsules. Look for a named species (Echinacea purpurea), a named plant part (above-ground / herba), and a standardised marker compound (alkylamides or cichoric acid). Avoid products that mix species without disclosing the ratio.
Dosage by outcome
| Outcome | Dose | Form | Duration | Population |
|---|---|---|---|---|
| Acute cold-onset (within 24h of symptoms) | 6 to 9 mL/day (fresh-plant juice equivalent), 3× daily | E. purpurea above-ground hydroalcoholic preparation | 2 weeks | |
| Cold-season prevention (winter prophylaxis) | 2 to 4 mL/day, Once daily | E. purpurea preparation | 16 weeks |
For acute cold-onset use, EMA HMPC suggests adult doses equivalent to roughly 6 to 9 mL of fresh-plant juice or tincture per day, divided into three doses, taken from the first symptoms for up to 10 days. Capsule doses of standardised extract vary widely by product, follow the label, which the manufacturer has dosed to match the clinical evidence for that specific preparation.
Safety
Interactions
| Substance | Severity | Mechanism | Recommendation |
|---|---|---|---|
| Immunosuppressants (tacrolimus, ciclosporin, methotrexate) | High | Echinacea modulates immune cell activity, antagonising the therapeutic immunosuppression these drugs provide. | Avoid combination. Discuss any herbal immune product with transplant or rheumatology team first. |
| Caffeine | Low | Echinacea inhibits CYP1A2, increasing caffeine plasma levels and clearance time. | Caffeine-sensitive users may want to reduce intake during echinacea courses. |
| Midazolam (and other CYP3A4 substrates) | Medium | Mixed CYP3A4 inhibition / induction; modest changes in midazolam clearance reported. | Inform anaesthetist before procedures requiring sedation. |
Drug interactions
Echinacea can modulate cytochrome P450 enzymes, primarily CYP3A4 and CYP1A2, in vitro. Clinical-magnitude interactions with caffeine and midazolam have been reported. The most important interaction in practice is the antagonism to immunosuppressants (tacrolimus, ciclosporin, methotrexate, biologics for autoimmunity).
Contraindications
Active or known autoimmune disease, organ transplant on immunosuppression, untreated HIV, known allergy to Asteraceae plants, age under 12 (limited paediatric safety data for preparations other than Echinacea purpurea juice in established products). Pregnancy and lactation data are limited; consult a clinician.
Side effects
| Effect | Frequency | Severity | Notes |
|---|---|---|---|
| Unpleasant taste / tingling tongue (tincture) | Common | Mild | Alkylamides cause a tingling sensation, a quality marker, not a problem. |
| Mild GI upset | Uncommon | Mild | Take with food. |
| Allergic skin reactions (rash, itching) | Uncommon | Moderate | More common in Asteraceae-allergic individuals. Stop and seek medical advice. |
| Anaphylaxis | Rare | Severe | Documented in Asteraceae-allergic individuals. Avoid in this group. |
Most users tolerate short-course echinacea well. Mild gastrointestinal upset, dry mouth, and a transient unpleasant taste are the most-reported. Skin rash is uncommon. Anaphylaxis is rare but documented in Asteraceae-allergic individuals.
Look-alikes
FAQs
Does echinacea actually work for colds?
The Cochrane review of echinacea preparations for the common cold found inconsistent results, with some Echinacea purpurea above-ground preparations modestly reducing duration when started at the first sign of symptoms. The overall evidence grade is C, promising but not conclusive. Product matters: extract type, plant part, and dose vary widely between brands.
Who should NOT take echinacea?
People with autoimmune conditions (rheumatoid arthritis, lupus, MS, type 1 diabetes), people on immunosuppressants after organ transplant, and those allergic to the Asteraceae/Compositae family (ragweed, daisies, chrysanthemums) should avoid echinacea or consult their doctor first. There is also limited safety data for pregnancy.
How long can I take echinacea?
Most clinical protocols use echinacea acutely, started at the first hint of cold symptoms and continued for 7 to 10 days. Continuous daily use beyond 8 weeks is not well-studied and is generally not recommended. Cycle on/off if you want to use it preventatively during cold season.
Echinacea purpurea, angustifolia, or pallida, which species is best?
Most modern clinical trials use Echinacea purpurea, mainly because it is easier to cultivate. E. angustifolia is the species traditionally used by indigenous North Americans and has a different alkylamide profile that some practitioners prefer. E. pallida is less commonly studied. For most consumer products, look for whole-plant or above-ground E. purpurea preparations with the species named on the label.
4 sources.
- Shah. Shah 2007. 2007.
- Jawad. Jawad 2012. 2012.
- Raso. Raso 2002. 2002.
- Zhai. Zhai 2009. 2009.
Legal notice: The depiction of historical significance and traditional use is context within our encyclopedia and not a health claim for any product, not a treatment promise, and not a substitute for medical advice. What may be stated on product labels, product pages, or in advertising is governed by the applicable legal requirements.